Reversal Dabigatran Anticoagulant Effect With Idarucizumab

Hemorrhage Clinical Trial

Official title:

Single Dose, Open Label, Uncontrolled, Safety Trial of Intravenous Administration of Idarucizumab to Paediatric Patients Enrolled From Ongoing Phase IIb/III Clinical Trials With Dabigatran Etexilate for the Treatment and Secondary Prevention of Venous Thromboembolism.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02815670
• Other study ID #: 1321.7
• Secondary ID: 2015-002177-37
• Status: Completed
• Phase: Phase 3
• Start date: September 7, 2016
• Est. completion date: October 19, 2019

Study information

• Verified date: March 2020
• Source: Boehringer Ingelheim
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The trial objective is to demonstrate the safety of idarucizumab, as assessed by the occurence of patients with drug related adverse events (including immune reactions) and all-cause mortality in paediatric venous thromboembolism patients treated with dabigatran in ongoing clinical trials who require emergency surgery/urgent procedures or patients who have life-threatening or uncontrolled bleeding which requires urgent intervention, when rapid reversal of the anticoagulant effect of dabigatran is needed.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1
• Est. completion date: October 19, 2019
• Est. primary completion date: October 19, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A to 18 Years

Eligibility

Inclusion criteria:

Patients taking dabigatran etexilate in the paediatric trials 1160.106 or 1160.108 are eligible for this trial if they meet the following criteria:

Group A:

• Overt bleeding judged by the treating physician to require a reversal agent.

• Currently taking dabigatran etexilate in the context of a clinical trial with dabigatran etexilate (1160.106 or 1160.108).

• Male or female patients from 0 to less than 18 years of age at the time of informed consent/assent for participation in trial 1160.106 or in trial 1160.108.

• Female patients of childbearing potential (defined as having experienced menarche) must have followed the contraception requirements according to the dabigatran trial 1160.106 or trial 1160.108 in which they are enrolled.

• Written informed consent provided by the patient (and/or the patient's legally accepted representative) and assent provided by the patient (if applicable) at the time of informed consent signature in accordance with Good Clinical Practice (GCP) and local legislation prior to admission to the trial. If the child is unable to give assent at the time of the emergency, the assent, when applicable will be obtained as soon as feasible.

Group B:

• A condition requiring an emergency surgery or invasive procedure where adequate haemostasis is required. Emergency is defined as need for surgery or intervention within the following 8 hours.

• Currently taking dabigatran etexilate in the context of a clinical trial with dabigatran etexilate (1160.106 or 1160.108).

• Male or female patients from 0 to less than 18 years of age at the time of informed consent/assent for participation in trial 1160.106 or in trial 1160.108.

• Female patients of childbearing potential (defined as having experienced menarche) must have followed the contraception requirements according to the dabigatran trial 1160.106 or trial 1160.108 in which they are enrolled.

• Written informed consent provided by the patient (and/or the patient's legally accepted representative) and assent provided by the patient (if applicable) at the time of informed consent signature in accordance with GCP and local legislation prior to admission to the trial. If the child is unable to give assent at the time of the emergency, the assent, when applicable will be obtained as soon as feasible.

Exclusion criteria:

Group A:

• Patients with minor bleeding (e.g. epistaxis, haematuria) who can be managed with standard supportive care.

• Patients with no clinical signs of bleeding.

• Patients with body weight < 2.5 kg

• Contraindications to trial medication including known hypersensitivity to the drug or its excipients; i.e. patients with hereditary fructose intolerance who may react to sorbitol.

• Female patients who are pregnant, nursing, or who plan to become pregnant while in the trial.

Group B:

• A surgery or procedure which is elective or where the risk of uncontrolled or unmanageable bleeding is low.

• Patients with body weight < 2.5 kg

• Contraindications to trial medication including known hypersensitivity to the drug or its excipients; i.e. patients with hereditary fructose intolerance who may react to sorbitol.

• Female patients who are pregnant, nursing, or who plan to become pregnant while in the trial.

Related Conditions & MeSH terms

• Hemorrhage

Intervention

Drug:
• Idarucizumab

Locations

Country	Name	City	State
Russian Federation	Children Rep.Clin.Hosp of MoH,Cardio Vas.surgery Dept, Kazan	Kazan
Russian Federation	Regional Clin.Hosp.1,Congen.heart defects&child.Cardiol.dept	Tyumen

Sponsors (1)

Lead Sponsor	Collaborator
Boehringer Ingelheim

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Drug-related Adverse Events (AEs)	Number of participants with drug-related adverse events (AEs) including immune reactions and all cause mortality during the trial.	From vial 1 of Idarucizumab until prematurely discontinued of the trial, up to 25 days
Secondary	Percent Change of Coagulation Time for Diluted Thrombin Time (dTT) and Ecarin Clotting Time (ECT) at 30 Minutes Post-dose Compared With Pre-dose	Percent change of coagulation time for diluted thrombin time (dTT) and ecarin clotting time (ECT) at 30 minutes (min) post-dose compared with pre-dose. Central blood sampling for dTT, ECT were to occur immediately prior to administration of each vial of Idarucizumab and post-dose at 30min, 4h, 12h and 24h.	At immediately prior to administration of vial 1 of Idarucizumab and 30 minutes (min) post vial 2 administration.
Secondary	Time to Achieve Reversal of the Dabigatran Effect (Based on the Coagulation Time for dTT and ECT)	Idarucizumab administration resulted in normalisation of dTT and ECT. Time to achieve reversal of anticoagulant effect of dabigatran based on the coagulation time for dTT and ECT, at any time point from the end of the second injection (vial 2) up to 24 hours (h). Reversal of the dabigatran effect at time t was defined as the 100 percent (%) *(pre-dose coagulation time - post-dose coagulation time at time t)/(pre-dose coagulation test - upper limit of normal).; Values equal to or higher than 100% were interpreted as reversal. Central blood sampling for dTT, ECT were to occur immediately prior to administration of each vial of Idarucizumab and post-dose at 30min, 4h, 12h and 24h.	From end of vial 2 of Idarucizumab up to 24h.
Secondary	Duration of Reversal of the Dabigatran Effect Sustained up to 24 Hours Post-dose (Based on the Coagulation Time for dTT and ECT)	Duration of reversal, defined as the time period a patient remained completely reversed based on dTT and ECT, up to 24 hours post-dose or restarting the treatment of anticoagulation. Central blood sampling for dTT, ECT were to occur immediately prior to administration of each vial of idarucizumab and post-dose at 30min, 4h, 12h and 24h.	From end of vial 2 of Idarucizumab up to 24h.
Secondary	Number of Participants With Cessation of Bleeding		From vial 1 of Idarucizumab through vial 2 of Idarucizumab, up to 24h 30min.
Secondary	Number of Participants Per Bleeding Status During the Trial	Numbers of participants whose bleeding had stopped, reduced, unchanged, worsened or not applicable during the trial were characterized.	From vial 1 of Idarucizumab until prematurely discontinued of the trial, up to 25 days
Secondary	Number of Participants With Clinical Conditions Contributing to Bleeding During the Trial	Number of participants with clinical conditions (trauma, surgery and use of antiplatelet) contributing to bleeding during the trial were characterized.	From vial 1 of Idarucizumab until prematurely discontinued of the trial, up to 25 days
Secondary	Number of Participants Developing Treatment-emergent Antidrug Antibodies (ADA) With Cross Reactivity to Idarucizumab		At day 25 post vial 2 of Idarucizumab administration, up to 1 day

External Links

•   Related Info